Recently added

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

Gratzke, Christian; feyerabend, susan; Werbrouck, Patrick; Vjaters, Egils; Shore, Neal; Carles, Joan (Oxford University Press, 2024-07-05)

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

ZENG, Qinghe; genestie, catherine; Rouleau, Etienne; de Bruyn, Marco; Grau Bejar, Juan Francisco; Yaniz-Galende, Elisa; OAKNIN, ANA (BMJ, 2024-07-01)

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells

Sanchez-Salinas, Mario Andrés; Martín-López, Ana Á.; Kwon, Mi; Rejeski, Kai; Gallur, Laura; Cecilia del Carmen, Carpio Segura; Barba, Pere; IACOBONI, GLORIA; Navarro Garces, Victor (Wiley, 2024-06-26)

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

Glaviano, Antonino; Wander, Seth; Baird, Richard; Yap, Kenneth C. H.; Lam, Hiu Yan; Toi, Masakazu; Serra, Violeta (Elsevier, 2024-06-25)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Robado de Lope, Lucía; Serna-Blasco, Roberto; Diz Tain, Pilar; provencio, mariano; Nadal, Ernest; Massuti, Bartomeu; MARTINEZ-MARTI, ALEX (Elsevier, 2024-06-26)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS ﻿

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer ﻿

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells ﻿

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment ﻿

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC ﻿

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC